Extrait

This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part. Once the MTD has been defined, the MTD expansion part will be opened for enrollment.

Critère d'inclusion

• Breast Cancer,colon cancer,Ovarian Cancer,Endometrium Cancer

Liens

• nct
• ictrp